Back to Conference page
UICC World Cancer Congress 2006
Bridging the Gap: Transforming Knowledge into Action
July 8-12, 2006, Washington, DC, USA
Methods:Peripheral blood monocytes of patients were cultured in the presence of IL-4&GM-CSF for 7 days. These immature dendritic cells (DCs) were then primed with autologous tumor lysates and allowed to mature in the presence of TNF-alpha and IL-1beta for 2-3 days. These DCs were characterized for phenotypic markers: HLA DP, DQ, DR, CD86, and CD14 by FACS analysis. Proliferation assays were done to characterize the functions of mature DCs. The study is an ongoing, randomized phase one clinical trial. So far 9 patients have been included in the trial.
Results:Phenotypic characterization showed that mature tumor-specific dendritic cells of the patients were all – HLA DP, DQ, DR (+++), CD86 (+++), CD14 (-). Proliferation assays indicate that priming can make the mature dendritic cells efficient in presenting antigens to autologous lymphocytes by inducing a strong proliferation response in these cells. 9 patients have completed vaccination, DTH response was observed in 3/9 patients. An objective tumour response not been observed yet. Minimal or no toxicity was observed in the patients so far.